95 related articles for article (PubMed ID: 12891909)
1. [The prostate cancer in the community of Madrid in 2000 I.- Incidence].
Herranz Amo F; Arias Funez F; Arrizabalaga Moreno M; Calahorra Fernández FJ; Carballido Rodríguez J; Diz Rodríguez R; Herrero Payo JA; Llorente Abarca C; Martín Martínez JC; Martínez-Piñeiro Lorenzo L; Mínguez Martínez R; Moreno Sierra J; Rodríguez Antolín A; Tamayo Ruiz JC; Turo Antona J
Actas Urol Esp; 2003 May; 27(5):323-34. PubMed ID: 12891909
[TBL] [Abstract][Full Text] [Related]
2. [The prostate cancer in the community of Madrid in 2000. II Presentation and diagnosis].
Herranz Amo F; Arias Funez F; Arrizabalaga Moreno M; Calahorra Fernández FJ; Carballido Rodríguez J; Diz Rodríguez R; Herrero Payo JA; Llorente Abarca C; Martín Martínez JC; Martínez-Piñeiro Lorenzo L; Mínguez Martínez R; Moreno Sierra J; Rodríguez Antolín A; Tamayo Ruiz JC; Turo Antona J
Actas Urol Esp; 2003 May; 27(5):335-44. PubMed ID: 12891910
[TBL] [Abstract][Full Text] [Related]
3. [National prostate cancer registry 2010 in Spain].
Cózar JM; Miñana B; Gómez-Veiga F; Rodríguez-Antolín A; Villavicencio H; Cantalapiedra A; Pedrosa E
Actas Urol Esp; 2013 Jan; 37(1):12-9. PubMed ID: 23102541
[TBL] [Abstract][Full Text] [Related]
4. Baseline PSA in a Spanish male population aged 40-49 years anticipates detection of prostate cancer.
Angulo JC; Viñas MA; Gimbernat H; Fata FR; Granados R; Luján M
Actas Urol Esp; 2015 Dec; 39(10):605-11. PubMed ID: 26099906
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010.
Cózar JM; Miñana B; Gómez-Veiga F; Rodríguez-Antolín A; Villavicencio H; ; Cantalapiedra A; Pedrosa E
BJU Int; 2012 Dec; 110(11 Pt B):E701-6. PubMed ID: 22989066
[TBL] [Abstract][Full Text] [Related]
6. [Prostate cancer in the Community of Madrid in the year 2000. IV. Treatment].
Herranz Amo F; Arias Funez F; Arrizabalaga Moreno M; Calahorra Fernández FJ; Carballido Rodríguez J; Diz Rodríguez R; Herrero Payo JA; Llorente Abarca C; Martín Martínez JC; Martínez-Piñeiro Lorenzo L; Mínguez Martínez R; Moreno Sierra J; Rodríguez Antolín A; Tamayo Ruíz JC; Turo Antona J
Actas Urol Esp; 2003 Jun; 27(6):418-27. PubMed ID: 12918148
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of the use of prostate specific antigen (PSA) in a health area of the Community of Madrid].
Páez Borda A; Luján Galán M; Llanes González L; Romero Cagigal I; de la Cal López MA; Miravalles González E; Berenguer Sánchez A
Actas Urol Esp; 2001; 25(10):698-703. PubMed ID: 11803775
[TBL] [Abstract][Full Text] [Related]
8. Actual incidence of prostate cancer in healthcare areas of the autonomous community of Castilla-Leon during 2014. CAPCYL registry data.
Virseda-Rodríguez AJ; Salvatierra C; García F; Sanz A; Gutiérrez E; Serrano JM; Valverde S; Polo C; Amón-Sesmero JH; Rodríguez V; Cortiñas R; Calleja J; Adriazola M; Gala L; Bermúdez R; Moya I; Szczesniewski RJ; López-Aramburu MA; Gómez-Veiga F
Actas Urol Esp (Engl Ed); 2018 Nov; 42(9):593-599. PubMed ID: 29292039
[TBL] [Abstract][Full Text] [Related]
9. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing.
Jacobsen SJ; Katusic SK; Bergstralh EJ; Oesterling JE; Ohrt D; Klee GG; Chute CG; Lieber MM
JAMA; 1995 Nov; 274(18):1445-9. PubMed ID: 7474190
[TBL] [Abstract][Full Text] [Related]
10. [Epidemiological trends in prostate cancer over the last years].
Luján Galán M; Páez Borda A; Chiva Robles V; Santonja Garriga C; Romero Cajigal I; Berenguer Sánchez A
Arch Esp Urol; 2004 Oct; 57(8):817-25. PubMed ID: 15560270
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer in Austria: impact of prostate-specific antigen test on incidence and mortality.
Vutuc C; Waldhoer T; Madersbacher S; Micksche M; Haidinger G
Eur J Cancer Prev; 2001 Oct; 10(5):425-8. PubMed ID: 11711757
[TBL] [Abstract][Full Text] [Related]
12. Socioeconomic variation and prostate specific antigen testing in the community: a United Kingdom based population study.
Morgan RM; Steele RJ; Nabi G; McCowan C
J Urol; 2013 Oct; 190(4):1207-12. PubMed ID: 23608675
[TBL] [Abstract][Full Text] [Related]
13. Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population.
Wallner LP; Frencher SK; Hsu JW; Chao CR; Nichol MB; Loo RK; Jacobsen SJ
BJU Int; 2013 Jun; 111(8):1245-52. PubMed ID: 23320750
[TBL] [Abstract][Full Text] [Related]
14. [Prostate cancer in the Community of Madrid in the year 2000. III. Study of tumor extent].
Herranz Amo F; Arias Funez F; Arrizabalaga Moreno M; Calahorra Fernández FJ; Carballido Rodríguez J; Diz Rodríguez R; Herrero Payo JA; Llorente Abarca C; Martín Martínez JC; Martínez-Piñeiro Lorenzo L; Mínguez Martínez R; Moreno Sierra J; Rodríguez Antolín A; Tamayo Ruíz JC; Turo Antona J
Actas Urol Esp; 2003 Jun; 27(6):411-7. PubMed ID: 12918147
[TBL] [Abstract][Full Text] [Related]
15. [Screening of cancer of the prostate: study in a Spanish population].
Herrero Payo JA; Montes Díaz MJ; Páez Borda A; Sánchez Sánchez E; Moreno Valle JA; Berenguer Sánchez A
Arch Esp Urol; 1996; 49(6):595-606. PubMed ID: 8929102
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality.
Larrañaga N; Galceran J; Ardanaz E; Franch P; Navarro C; Sánchez MJ; Pastor-Barriuso R;
Ann Oncol; 2010 May; 21 Suppl 3():iii83-89. PubMed ID: 20427365
[TBL] [Abstract][Full Text] [Related]
17. Trends in incidence and mortality rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in southeastern Netherlands, 1971-1995.
Post PN; Kil PJ; Crommelin MA; Schapers RF; Coebergh JW
Eur J Cancer; 1998 Apr; 34(5):705-9. PubMed ID: 9713278
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.
Bratt O; Berglund A; Adolfsson J; Johansson JE; Törnblom M; Stattin P;
Scand J Urol Nephrol; 2010 Dec; 44(6):384-90. PubMed ID: 20624113
[TBL] [Abstract][Full Text] [Related]
19. Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.
Thomas R; Glasziou P; Rychetnik L; Mackenzie G; Gardiner R; Doust J
BMJ Open; 2014 Dec; 4(12):e005691. PubMed ID: 25539779
[TBL] [Abstract][Full Text] [Related]
20. [Incidental prostatic cancer].
Herranz Amo F; Díez Cordero JM; Verdú Tartajo F; Leal Hernández F; Bielsa Carrillo A; García Burgos J; Subirá Ríos D
Actas Urol Esp; 1999; 23(10):848-52. PubMed ID: 10670126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
